(Q35738188)

10 August 2017

1 reference

title

Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer (English)

1 reference

10 August 2017

1 reference

Fernand Labrie

1

1 reference

10 August 2017

publication date

1 May 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

25

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

305-313

1 reference

Potent inhibitory activity of [D-Leu6, Des-Gly-NH2(10)]LHRH ethylamide on LH/hCG and PRL testicular receptor levels in the rat.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

Inhibition of testicular luteinizing hormone receptor level by treatment with a potent luteinizing hormone-releasing hormone agonist of human chorionic gonadotropin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

Patients' choice of treatment in stage D prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

Large Shionogi tumors lose their responsiveness to flutamide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men**Supported in part by the National Cancer Institute of Canada; Hoechst AG, Frankf

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

21 January 2018

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

Effects of long term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

Unresponsiveness of the reproductive organs of the male mouse to treatment with a potent luteinizing hormone-releasing hormone agonist (ICI-118,630)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2004.TB02791.X

10.1002/J.1939-4640.2004.TB02791.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference